Treatment (cyclophosphamide, MUC1-activated T-cells) for Refractory Plasma Cell Myeloma

Phase-Based Progress Estimates
Mayo Clinic Hospital in Arizona, Phoenix, AZ
Refractory Plasma Cell Myeloma+3 More
Autologous MUC1-activated T-cells - Biological
All Sexes
What conditions do you have?

Study Summary

This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for expression of the MUC1 protein. T-cells are infection fighting blood cells that can kill cancer cells. MUC1-activated T-cells are made from the body's own T cells. The manufactured T-cells are made to target the MUC1 genetic marker and may help the body's immune system identify and kill cancer cells.

Eligible Conditions

  • Refractory Plasma Cell Myeloma
  • Recurrent Plasma Cell Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Refractory Plasma Cell Myeloma

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to 4 years

Year 4
Overall survival
Year 4
Progression-free survival
Up to 4 years
Clinical response
Incidence of adverse events

Trial Safety

Safety Progress

1 of 3

Other trials for Refractory Plasma Cell Myeloma

Trial Design

1 Treatment Group

Treatment (cyclophosphamide, MUC1-activated T-cells)
1 of 1
Experimental Treatment

18 Total Participants · 1 Treatment Group

Primary Treatment: Treatment (cyclophosphamide, MUC1-activated T-cells) · No Placebo Group · Phase 1

Treatment (cyclophosphamide, MUC1-activated T-cells)Experimental Group · 2 Interventions: Autologous MUC1-activated T-cells, Cyclophosphamide · Intervention Types: Biological, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 4 years
Closest Location: Mayo Clinic Hospital in Arizona · Phoenix, AZ
Photo of Phoenix  1Photo of Phoenix  2Photo of Phoenix  3
2022First Recorded Clinical Trial
3 TrialsResearching Refractory Plasma Cell Myeloma
2 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a serum free light chain (FLC) ≥ 10 mg/L with an abnormal free light chain ratio.
Plasma cells in bone marrow > 30% of total nucleated cells.
1 lesion that has a single diameter of ≥ 2 cm measured by CT or MRI or the CT portion of the PET/CT.
You have skin lesions in at least one area of the body.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.